ULBI · Ultralife
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $18.11
Note written ·
Price against the kill line
13.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $18.11, on record since 11 November 2026. The shares are up 116.4% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $18.11, above the $16.00 cash offer and the $15.83 52-week high, which would show the shares leading the S&P 500; a competing proposal or a raised EnerSys offer above $16.00 per share would also prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Industrials
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 48.3
- Revenue, change on a year (%)
- +11.3
- Gross margin (%)
- 27.5
- Operating margin (%)
- 6.6
- Free cash flow, four quarters ($M)
- −0.7
- Net cash, cash less debt ($M)
- −42.9
- Enterprise value to sales (×)
- 1.6
- Free-cash-flow yield (%)
- −0.3
All filed numbers
What Ultralife reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 48.3 | +11.3 | 27.5 | 6.6 |
| first filed | 47.9 | −1.3 | 28.9 | 7.2 |
| first filed | 47.4 | −6.5 | 21.3 | −0.5 |
| first filed | 48.5 | +10.6 | 24.9 | −21.9 |
| first filed | 43.4 | +21.5 | 22.2 | −2.2 |
| first filed | 48.6 | +13.0 | 23.9 | 4.6 |
| Pre-tax income ($M) | 2.7 |
| Net income ($M) four quarters: −3.0 | 2.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +0.3 |
| Operating cash flow ($M) | 2.0 |
| Capital spending ($M) | 2.7 |
| Free cash flow ($M) | −0.7 |
| Cash and short-term investments ($M) | 7.6 |
| Debt ($M) non-current long-term debt plus current maturities | 50.5 |
| Net cash, cash less debt ($M) | −42.9 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 35.8 |
| Inventory ($M) | 62.3 |
| Shareholders' equity ($M) | 135 |
| Market value ($M) | 262 |
| Enterprise value, market value plus net debt ($M) | 305 |
| Enterprise value to sales (×) | 1.6 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.9 |
| Free-cash-flow yield (%) | −0.3 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 0.5% of shares outstanding sold short, 3.9 days of average trading to cover, −11.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $2.5M | $0 |
The thesis
Ultralife Corporation trades as a capped claim on EnerSys's $16.00-per-share cash offer, so the shares are more likely to lag the S&P 500 than lead it over the next three months. US antitrust clearance, UK national security clearance and the tender offer, first due to expire on 3 December 2026, decide whether holders are paid.
EnerSys agreed on 27 October 2026 to buy Ultralife for about $320 million including net debt, a 166% premium to the $6.01 close on 26 October 2026, according to the merger press release. The shares closed at $15.75 on 11 November 2026, under the $16.00 cash price. That close means the market treats completion as likely and leaves only a small discount for time and regulatory risk.
EnerSys's fiscal second-quarter release on 11 November 2026 said the deal "is expected to close in the fourth fiscal quarter of 2027" and "remains subject to customary closing conditions, including the receipt of required regulatory approvals." The release gave no update on either clearance. Searches of company news and filings on 12 November 2026 found no competing bid, no notice that the US waiting period has ended and no amendment moving the expiry date. A competing proposal above $16.00 would show the upside is not capped.
Bullish and bearish views on Ultralife Corporation
The bull case on Ultralife Corporation (ULBI), in brief: cash offer with no financing condition. The bear case: upside is small, downside is large.
Bull case
- Cash offer with no financing condition. The merger agreement has no financing condition. EnerSys reported $275.5 million of cash and net leverage of 0.8 times at 4 October 2026 in its 11 November 2026 results release.
- Acquirer reaffirmed its timetable. EnerSys's 11 November 2026 release kept a close in its fiscal fourth quarter of 2027. That fits the first-quarter 2027 timing it gave on 27 October 2026.
- Largest holder is committed. Chair Bradford Whitmore and affiliated entities, with 6,708,835 shares or about 40.3%, signed a support agreement to tender, the Schedule 14D-9 filed 28 October 2026 shows. The offer needs more than 50% of outstanding shares.
- Board and insiders back the price. The board unanimously recommended the offer, and each executive officer and director intends to tender, per the Schedule 14D-9. StoneX gave its fairness opinion on 27 October 2026.
- The price was negotiated upward. EnerSys opened at $12.00 to $14.00 per share on 6 July 2026 and reached $16.00 on 9 October 2026 after Ultralife countered at $18.00 and $17.00, per the Schedule 14D-9.
- The business improved into the deal. Ultralife reported on 5 November 2026 that third-quarter revenue rose to $48.271 million from $43.371 million a year earlier. Earnings per share were $0.14 against a $0.07 loss, per the results release and the 10-Q for the quarter ended 30 September 2026.
Bear case
- Upside is small, downside is large. The $16.00 cash price sits just above the $15.75 close on 11 November 2026, while the last price before the deal was $6.01 on 26 October 2026. A failed deal would reopen most of that gap.
- Two regulators must clear it. The offer is conditioned on the US Hart-Scott-Rodino (HSR) antitrust waiting period and UK National Security and Investment Act (NSIA) clearance, and EnerSys is not required to accept divestitures, per the Schedule 14D-9. EnerSys's 11 November 2026 release did not report either clearance.
- Break protection is modest. The reverse termination fee is $10.3 million and is payable only in specified antitrust-related circumstances, per the Schedule 14D-9.
- Standalone value rests on a steep plan. Management's projections in the Schedule 14D-9 lift revenue from $208.3 million in 2026 to $266.2 million in 2029. StoneX's comparable-company range was $9.1 to $13.3 per share.
- Debt would remain after a break. At 30 September 2026 Ultralife had $45.125 million of term loan principal and $5.875 million drawn on its revolver against $8.628 million of cash, including $1.0 million restricted, per the 10-Q.
- Price challenge is being probed. Ademi LLP said on 28 October 2026 it is investigating whether the buyout gives fair value to shareholders. The terms have not changed since.
Price setup
The shares closed at $15.75 on 11 November 2026, against a 52-week intraday high of $15.83 on 10 November 2026 and a close of $15.79 that day. Closes have held in a narrow range, from $15.62 on 4 November 2026 to $15.79 on 10 November 2026, per adjusted daily closes.
The shares are up 111.7% over three months from $7.44 on 13 August 2026, almost all of it from the repricing after the 27 October 2026 announcement. The 50-day moving average of $8.17 and the 200-day moving average of $6.84, both as of 11 November 2026, still reflect the pre-deal price and say little about where the shares trade while the offer stands.
The $16.00 cash price is the effective ceiling unless a rival bid or a raised offer appears. The $6.01 close of 26 October 2026 marks where the shares last traded on their own business. Movement between those levels now tracks perceived deal risk and time to payment.
Catalysts ahead
- ~25 November 2026 (est.): End of the 15-day HSR waiting period for the cash tender offer, if the filing was made by the 10-business-day deadline in the merger agreement. Expiry without a second request would satisfy the US condition and leave UK clearance and the minimum tender.
- 3 December 2026: Initial expiry of the EnerSys tender offer at 5:00 p.m. New York City time. An extension fits EnerSys's fiscal fourth-quarter 2027 closing guidance; a termination or regulatory objection would break the case.
- 27 April 2027: Outside date under the merger agreement, subject to extensions. It marks the point at which the deal can lapse if conditions remain unmet.
What would change the view
A daily close above $18.11, above the $16.00 cash offer and the $15.83 52-week high, which would show the shares leading the S&P 500; a competing proposal or a raised EnerSys offer above $16.00 per share would also prove this call wrong.
What it trades with
While the deal stands, the shares track the probability and timing of the $16.00 payment rather than the S&P 500 or defense-equipment suppliers. Gains in the broader market or in defense peers do not lift Ultralife above the cash price.
The link to EnerSys (ENS) runs through deal risk. EnerSys reported second-quarter net sales of $949.9 million on 11 November 2026, below its $955 million to $995 million guidance, with adjusted earnings per share of $3.22. Its own results matter to Ultralife only if they affected its ability or willingness to close. If the deal failed, Ultralife would revert to trading as a small battery and communications-systems supplier to defense customers, last priced on its own at $6.01 on 26 October 2026.
The evidence, claim by claim (8)
- EnerSys agreed to acquire Ultralife for $16.00 per share in cash, about $320 million including net debt and a 166% premium to the $6.01 close on 26 October 2026. EnerSys press release and Ultralife Form 8-K, 27 October 2026 · as of
- The tender offer and withdrawal rights expire at 5:00 p.m. New York City time on 3 December 2026 unless extended. Schedule TO-T offer documents filed 28 October 2026 · as of
- EnerSys said the Ultralife deal is expected to close in its fourth fiscal quarter of 2027 and remains subject to customary closing conditions, including required regulatory approvals. EnerSys fiscal Q2 2027 results release, 11 November 2026 · as of
- EnerSys reported $275.5 million of cash and net leverage of 0.8 times at 4 October 2026; second-quarter net sales were $949.9 million against $955 million to $995 million guidance. EnerSys fiscal Q2 2027 results release, 11 November 2026 · as of
- Bradford Whitmore and affiliated entities beneficially own 6,708,835 shares, about 40.3% of those outstanding, and agreed to tender under a support agreement. Ultralife Schedule 14D-9 · as of
- The company and reverse termination fees are each $10.3 million; the reverse fee is payable in specified antitrust-related circumstances. Ultralife Schedule 14D-9 · as of
- Third-quarter revenue was $48.271 million against $43.371 million a year earlier; EPS was $0.14 against a $0.07 loss. Ultralife Q3 2026 results release 5 November 2026 and 10-Q · as of
- Ultralife had $45.125 million of term loan principal, $5.875 million drawn on its revolver and $8.628 million of cash, including $1.0 million restricted. Ultralife 10-Q for the quarter ended 30 September 2026 · as of
Sources
- Currency shifts left battery maker EnerSys' sales below guidance as earnings per share rose 34%. · stocktitan.net ·
- ULTRALIFE CORP - Form SC 14D9 - FY2026 · sec.gov
- ULTRALIFE CORP - Form SC TO-T - FY2026 · sec.gov
- ULTRALIFE CORP - Form 10-Q - FY2026 · sec.gov
- EnerSys To Acquire Ultralife, Expanding Differentiated Battery Technologies and Accelerating Growth in Defense Market · investor.enersys.com
- ULTRALIFE CORP - Form 8-K - FY2026 · sec.gov ·
Related · shared themes
GPN
Global Payments
Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
BMBL
Bumble
Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing…
BRZE
Braze
Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P…